urogenital neoplasms


Summary: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.

Top Publications

  1. Stevens M. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol. 2005;6:77-84 pubmed
    ..An important issue is the overall cost of cure in relation to the treatment received and the need for better selection of patients most likely to benefit from this approach to therapy...
  2. Mondaini N, Palli D, Saieva C, Nesi G, Franchi A, Ponchietti R, et al. Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol. 2005;47:468-73 pubmed
    ..We report our experience with this type of tumours in a multicenter study carried out in a single region of Central Italy (Tuscany)...
  3. Dotan Z, Tal R, Golijanin D, Snyder M, Antonescu C, Brennan M, et al. Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol. 2006;176:2033-8; discussion 2038-9 pubmed
    ..Urological sarcomas are rare. We describe a continued single institutional experience during 25 years...
  4. Castellino S, McLean T. Pediatric genitourinary tumors. Curr Opin Oncol. 2007;19:248-53 pubmed
    ..We will review the 2005 and 2006 literature on pediatric genitourinary tumors...
  5. Lam C, Funaro D. Extramammary Paget's disease: Summary of current knowledge. Dermatol Clin. 2010;28:807-26 pubmed publisher
    ..This extensive review takes a closer look at what is known about EMPD and the conclusions that have been drawn from this information. This article also provides a practical approach to patients with EMPD...
  6. Grossman R, Pedroso F, Byrne M, Koniaris L, Misra S. Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers?. J Surg Oncol. 2011;104:604-12 pubmed publisher
    ..EPSCC patients who are potential candidates for surgical resection or radiation therapy may benefit from these treatments. ..
  7. Wawroschek F, Harzmann R, Weckermann D. [Value of sentinel node biopsy for urological tumors]. Urologe A. 2005;44:630-4 pubmed
    ..It is in fact essential that the accuracy of the method - the feasibility of which can be influenced by numerous factors - be assessed by comparison with a standard lymphadenectomy performed in one's own center. ..
  8. Halachmi S, Kakiashvili D, Meretyk S. A review on hematuria in children. ScientificWorldJournal. 2006;6:311-7 pubmed
    ..This article presents the major diseases that may cause hematuria in children and suggests an evaluation algorithm for the pediatric urologist. ..
  9. Pozzi Mucelli R, Faccioli N, Manfredi R. Imaging findings of genitourinary tumors in the elderly. Radiol Clin North Am. 2008;46:773-84, vi pubmed publisher
    ..This article considers first the neoplastic genitourinary pathologies and second the non-neoplastic genitourinary pathologies. ..

More Information

Publications116 found, 100 shown here

  1. Williams S, Rabbani F. Complications of lymphadenectomy in urologic surgery. Urol Clin North Am. 2011;38:507-18, vii pubmed publisher
    ..With improvements in surgical technique and perioperative care, the morbidity associated with lymphadenectomy may be minimized. ..
  2. Ma B, Maraj B, Tran N, Knoff J, Chen A, Alvarez R, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012;17:469-92 pubmed publisher
    ..As research in the development of HPV vaccines continues, we may generate effective strategies to control HPV-associated malignancies. ..
  3. Sanchez Salmon A, Barandela Salgado J, Ruibal Morell A. PET in abdominal pathology: advantages and limitations. Abdom Imaging. 2006;31:174-81 pubmed
    ..Thus, many changes in the choice of treatment are seen. However, it is very important to know that sometimes there is a lack of specificity that has to be considered. ..
  4. Song Y, He J, Wu L, Wang L, Wang J. [Treatment and prognosis of extrapulmonary small cell carcinoma of 243 cases]. Zhonghua Zhong Liu Za Zhi. 2010;32:132-8 pubmed
    ..These differences may influence the choice of therapeutic strategy. Multimodal therapy, combination of chemo- and radio-therapy after surgical resection may improve the outcome of EPSCC. ..
  5. Donato D, Johnson M, Yang X, Zynger D. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59:1229-39 pubmed publisher
    ..Knowledge of expression overlap between these entities may prevent incorrect interpretation of immunohistochemical results, particularly if limited tissue is available. ..
  6. Nolan M, Kogan L, Griffin L, Custis J, Harmon J, Biller B, et al. Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs. J Vet Intern Med. 2012;26:987-95 pubmed publisher
    ..As compared with previous reports in the veterinary literature, inclusion of IM/IGRT in multimodal treatment protocols for CGUC can result in superior survival times; controlled prospective evaluation is warranted. ..
  7. Amari F, Beyer D, Diedrich K, Weichert J. Fetal intra-abdominal tumors: assessment of spectrum, accuracy of prenatal diagnosis, perinatal outcome and therapy at a tertiary referral center. Eur J Obstet Gynecol Reprod Biol. 2013;167:160-6 pubmed publisher
    ..Pre- and post-natal invasive surgical interventions were mandatory in only a small number of cases. ..
  8. Awsare N, Krishnan J, Boustead G, Hanbury D, McNicholas T. Complications of vasectomy. Ann R Coll Surg Engl. 2005;87:406-10 pubmed
    ..Vasectomy, though safe and relatively simple, requires a high level of expertise to minimise complications. Adequate pre-operative counselling is essential to increase patient acceptability of this method of permanent contraception. ..
  9. Rigamonti W, Iafrate M, Milani C, Capizzi A, Bisogno G, Carli M, et al. Orthotopic continent urinary diversion after radical cystectomy in pediatric patients with genitourinary rhabdomyosarcoma. J Urol. 2006;175:1092-6; discussion 1096 pubmed
    ..It represents a safe long-term option and offers good quality of life after disfiguring surgery. In fact, patients are able to void spontaneously through the urethra. ..
  10. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008;34:183-92 pubmed
  11. Maheshwari A, Chiappetta G, Kugler C, Pitcher J, Temple H. Metastatic skeletal disease of the foot: case reports and literature review. Foot Ankle Int. 2008;29:699-710 pubmed
    ..The common primary sites are the genito-urinary, lungs, breast, and the colo-rectum. Treatment is usually palliative to reduce pain and maintain function. ..
  12. Kirchoff D, Deutsch G, Foshag L, Lee J, Sim M, Faries M. Evolving Therapeutic Strategies in Mucosal Melanoma Have Not Improved Survival Over Five Decades. Am Surg. 2016;82:1-5 pubmed
    ..Although multiple surgical interventions portend a better outcome in patients with mucosal melanoma, adjuvant treatment decisions must be individualized. ..
  13. Machtens S, Boerner A, Hofmann M, Knapp W, Jonas U. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors]. Urologe A. 2004;43:1397-409 pubmed
    ..For all other tumors of the urogenital tract this proof is still awaited. ..
  14. Steenbergen R, de Wilde J, Wilting S, Brink A, Snijders P, Meijer C. HPV-mediated transformation of the anogenital tract. J Clin Virol. 2005;32 Suppl 1:S25-33 pubmed
  15. Eschwege P. [Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers]. Bull Cancer. 2004;91 Suppl 2:S113-6 pubmed
    ..Cox2 inhibitors present anticancer properties demonstrated in wide varieties of cellular and animal models. Human applications are currently tested in many clinical trials for bladder, prostate and uterine carcinomas. ..
  16. Skerlev M, Ljubojevic S. [The specifities of the HPV-genital infections in males]. Med Glas (Zenica). 2010;7:89-95 pubmed
    ..Approaches to this include prophylactic vaccines such as quadrivalent HPV vaccine for both men and women. ..
  17. Henk H, Kaura S. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. J Med Econ. 2012;15:185-94 pubmed publisher
    ..Without IV-BPs, PC patients have significantly larger risks of fracture and death compared with ZOL-treated patients, and benefits appear to be larger with increasing persistency on ZOL. ..
  18. Sanchez A, Rodríguez D, Allard C, Bechis S, Sullivan R, Boeke C, et al. Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort. Urol Oncol. 2016;34:166.e7-14 pubmed publisher
    ..Clinicians and patients must be aware of the poor disease-specific outcomes associated with primary GU melanoma. Most importantly, women fare worse than men and mucosal melanomas have worse outcomes compared to cutaneous melanomas. ..
  19. Périer A, Savey L, Marcelin A, Serve P, Saadoun D, Barete S. De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. Arthritis Rheumatol. 2017;69:2241-2246 pubmed publisher
    ..The safety of RTX, especially in nonlymphomatous disorders, should be carefully evaluated in patients at risk of HHV-8 tumors. ..
  20. Rexer H. [The Association of Urological Oncology (AOU) German Cancer Society e.V. The competent counterpart for research in Uro-oncology]. Urologe A. 2005;44:408-11 pubmed
    ..In this article, the organisation's structure is described in detail. Various aspects of AUO work, carried out over the years, are highlighted, and data presented on the outcome of studies. ..
  21. Kanazi G, Aouad M, Jabbour Khoury S, Al Jazzar M, Alameddine M, Al Yaman R, et al. Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. Acta Anaesthesiol Scand. 2006;50:222-7 pubmed
    ..Dexmedetomidine (3 microg) or clonidine (30 microg), when added to intrathecal bupivacaine, produces a similar prolongation in the duration of the motor and sensory block with preserved hemodynamic stability and lack of sedation. ..
  22. Small E, Halabi S, Kantoff P, D Amico A, Stadler W, Kelley W, et al. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006;12:3596s-600s pubmed
    ..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients. ..
  23. Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int. 2010;85:1-10 pubmed publisher
    ..Cross-sectional imaging studies for response assessment might be obtained after each 2 cycles of systemic therapy to early stratify responders from non-responders. ..
  24. Brassesco M, Valera E, Bonilha T, Scrideli C, Carvalho De Oliveira J, Pezuk J, et al. Secondary PSF/TFE3-associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma. Cancer Genet. 2011;204:108-10 pubmed publisher
    ..The presence of the PSF-TFE3 fusion has only been described in a very limited number of cases. Our report expands the spectrum of tumors in which RCC can arise in the pediatric age group after chemotherapy. ..
  25. Ouban A, Hamdan H, Hakam A, Ahmed A. Claudin-1 expression in squamous cell carcinomas of different organs: comparative study of cancerous tissues and normal controls. Int J Surg Pathol. 2012;20:132-8 pubmed publisher
    ..Knowledge of this fact is important in planning biologic therapy targeting claudin-1. ..
  26. Hensel J, Flaig T, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2013;10:41-51 pubmed publisher
    ..In our opinion, dormancy-directed therapies will prove most effective when the effect of these cumulative contributions are understood and targeted. ..
  27. Herbst R, Bajorin D, Bleiberg H, Blum D, Hao D, Johnson B, et al. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24:190-205 pubmed
    ..I want to thank the Editorial Board members, the Specialty Editors, and the ASCO Cancer Communications Committee for their dedicated work to develop this report, and I hope you find it useful. ..
  28. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2006;97:1351-2 pubmed
  29. Savoia P, Osella Abate S, Comessatti A, Nardo T, Marchio C, Pacchioni D, et al. Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. J Clin Pathol. 2008;61:179-83 pubmed
  30. Li C, Ekwueme D, Rim S, Tangka F. Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004. Urology. 2010;76:528-35 pubmed publisher
    ..Urogenital cancers impose a considerable health and economic burden in terms of premature deaths and productivity losses in men in the United States, particularly among the elderly and non-Hispanic whites and blacks. ..
  31. Petralia G, Thoeny H. DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging. 2010;10 Spec no A:S112-23 pubmed publisher
    ..As the ADC is generally reduced in malignant tumours and increased under inflammatory conditions, reduced ADC values were expected in patients with lymph node metastases. ..
  32. He H, Gonzalez A, Robinson E, Yang W. Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast. AJR Am J Roentgenol. 2014;202:1140-8 pubmed publisher
    ..Knowledge of these unusual metastatic manifestations and disease patterns may aid in differentiating distant metastatic disease from secondary primary cancers and help plan appropriate therapy. ..
  33. Barchana M. Epidemiological aspects in Western countries. Tunis Med. 2005;83 Suppl 12:11 pubmed
  34. Seeber S, Strumberg D. [Metastases with CUP syndrome]. Urologe A. 2006;45:614-9 pubmed
    ..For all other patients, toxic therapies are recommended only for patients with good functional status, for palliation of symptoms when they develop, and for continuous support of the quality of life. ..
  35. Kouba E, Wallen E, Pruthi R. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180:444-50 pubmed publisher
    ..In the meantime research is needed to find methods of urinary diversion and pharmacological intervention for symptomatic relief without compromising quality of life in patients at the end of life. ..
  36. Smollich M, Wülfing P. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther. 2008;8:1481-93 pubmed publisher
    ..Data indicate a future role of ET(A)R antagonists in oncologic therapies. ..
  37. Hrbacek J, Konopásek P, Eis V, Hamsikova E, Tachezy R, Pokorny J, et al. [Urologic complications of HIV infection]. Cas Lek Cesk. 2010;149:115-9 pubmed
    ..Impairment of kidney function is usually caused by HIV-associated nephropathy. Acute renal failure can also occur. Indinavir causes urinary stones formation. Male circumcision is an effective method of HIV transmission prevention. ..
  38. Critselis E, Panagiotakos D, Machairas A, Zampelas A, Critselis A, Polychronopoulos E. Risk and predictive factors of hypoalbuminemia in cancer patients following extensive abdominal surgery despite total parenteral nutritional support. Int J Food Sci Nutr. 2012;63:208-15 pubmed publisher
    ..Therefore, despite TPN, cancer patients who underwent EAS had an elevated risk of postoperative hypoalbuminemia. Additional tailored nutritional support among this group is necessary to deter adverse clinical outcomes. ..
  39. Darragh T, Colgan T, Thomas Cox J, Heller D, Henry M, Luff R, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32:76-115 pubmed publisher
    ..The implemented recommendations will facilitate communication between pathologists and their clinical colleagues and improve accuracy of histologic diagnosis with the ultimate goal of providing optimal patient care. ..
  40. Chinaud F, Slota L, Souques M, Asselain B, Blanchon B, Dubois G, et al. [Five-year survival of Ile-de-France cancer patients diagnosed in 1994]. Rev Epidemiol Sante Publique. 2005;53:477-90 pubmed
    ..Besides providing information useful to determine mortality and incidence, the health insurance data offer additional insight to cancer epidemiology and contribute to better knowledge of this disease. ..
  41. Albers P, Gschwend J, Miller K. [15 years Urologic Oncology Professional Group]. Urologe A. 2006;45:1187-9, 1191-2 pubmed
  42. Tagalakis V, Tamim H, Blostein M, Collet J, Hanley J, Kahn S. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol. 2007;8:395-402 pubmed
    ..Further investigation, with more complete assessment of confounders and that addresses the effect of warfarin on mortality of prostate cancer, is warranted. ..
  43. Bujak R, Daghir E, Rybka J, Koslinski P, Markuszewski M. Metabolomics in urogenital cancer. Bioanalysis. 2011;3:913-23 pubmed publisher
    ..This novel metabolomic approach has the potential to provide more information about the pathophysiological status of an organism and distinguish precancerous and cancerous stages. ..
  44. Stöhr C, Stohr R, Rogler A, Amann K, Knüchel Clarke R, Hartmann A. [Personalized urooncology based on molecular uropathology: part 1: what is diagnostic routine?]. Urologe A. 2013;52:970-5 pubmed publisher
    ..As a consequence the diagnostic procedures are no longer limited to histology and immunohistochemistry but also include the analysis of genetic alterations (mutations and chromosomal aberrations). ..
  45. Booth L, Roberts J, Cruickshanks N, Conley A, Durrant D, Das A, et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol. 2014;85:408-19 pubmed publisher
    ..Collectively our data demonstrate that the combination of PDE5 inhibitors with standard of care chemotherapy agents for gastrointestinal/genitourinary cancers represents a novel modality. ..
  46. Leto G, Incorvaia L, Badalamenti G, Arcara C, Fulfaro F, Tumminello F, et al. Tumor markers in urogynaecological tumors. Tunis Med. 2005;83 Suppl 12:28 pubmed
  47. Reddy G, Tyagi P. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA; June 2-6, 2006. Clin Genitourin Cancer. 2006;5:18-22 pubmed
  48. Engel J, Schally A, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm. 2007;4:652-8 pubmed
    ..The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers. ..
  49. Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012;48:456-64 pubmed publisher
    ..In view of the low number of cases and the fact that one third to one half of the patients die of their disease, centralisation of treatment of these rare tumours to a select number of specialist centres should be promoted. ..
  50. Funaro D, Krasny M, Lam C, Desy D, Sauthier P, Bouffard D. Extramammary Paget disease: epidemiology and association to cancer in a Quebec-based population. J Low Genit Tract Dis. 2013;17:167-74 pubmed publisher
    ..Extramammary Paget disease is more commonly found on the vulva of older women and frequently recurs. Recurrence was not associated to margin status, which would support a more conservative therapeutic approach. ..
  51. Hadway P, Lynch M, Heenan S, Watkin N. Current status of dynamic lymphoscintigraphy and sentinel lymph-node biopsy in urological malignancies. BJU Int. 2005;96:1235-9 pubmed
  52. Besarani D, Cranston D. Urological malignancy after renal transplantation. BJU Int. 2007;100:502-5 pubmed
    ..In the presence of metastatic disease, chemotherapy treatment with adjustment or cessation of immunosuppressive therapy is required...
  53. Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, Nakamura K, et al. Frequency and risk factors of various complications after computed tomography-guided radiofrequency ablation of lung tumors. Cardiovasc Intervent Radiol. 2008;31:122-30 pubmed
    ..To retrospectively determine the frequency and risk factors of various side effects and complications after percutaneous computed tomography-guided radiofrequency (RF) ablation of lung tumors...
  54. Vanderstraeten E, Bogaert L, Bravo I, Martens A. EcPV2 DNA in equine squamous cell carcinomas and normal genital and ocular mucosa. Vet Microbiol. 2011;147:292-9 pubmed publisher
    ..The close relatives of EcPV2 are associated to cutaneous lesions, and this virus is not related to high-risk human papillomaviruses causing cervical cancer. Thus, similar viral tropism does not imply close evolutionary relationship...
  55. Buckley K. Pediatric genitourinary tumors. Curr Opin Oncol. 2011;23:297-302 pubmed publisher
    ..To review the 2009/2010 literature on pediatric genitourinary tumors and highlight the most significant publications...
  56. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729-36 pubmed publisher
    ..A recent meta-analysis of randomized trials suggested that use of angiotensin receptor blockers (ARBs) may be associated with a modestly increased risk of incident cancer, particularly lung cancer...
  57. Printz C. FDA approves Gardasil 9 for more types of HPV. Cancer. 2015;121:1156-7 pubmed publisher
  58. Chang Y, Wu C, Lee Y, Huang P, Kao Y, Shiau M. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology. 2004;64:687-92 pubmed
    ..To evaluate prospectively the prognostic power of urinary nuclear matrix protein-22 (NMP-22) for bladder cancer in Taiwanese screening and surveillance settings...
  59. Romero F, Broglio M, Pires S, Roca R, Guibu I, Perez M. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol. 2005;31:117-24 pubmed
    ..The percutaneous nephrostomy is a safe and effective method for relief the obstruction; however the indications of such procedures have been questioned in patients with poor prognosis...
  60. Shioda Y, Kumagai M. [Tumor markers of childhood cancer]. Gan To Kagaku Ryoho. 2005;32:699-704 pubmed
    ..Recently, these molecular markers have also come to be used for the detection of minimal residual disease. Such a system can be regarded as a kind of tumor marker...
  61. Soerjomataram I, Louwman W, Lemmens V, de Vries E, Klokman W, Coebergh J. Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972-2001. Eur J Cancer. 2005;41:2331-7 pubmed
    ..However, breast cancer has an inverse relationship to risk of cervical cancer. Changes in behavioural risk factors are important for lowering the risk of second cancer after breast cancer...
  62. Bassal M, Mertens A, Taylor L, Neglia J, Greffe B, Hammond S, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476-83 pubmed
    ..To determine the risk of subsequent carcinomas other than breast, thyroid, and skin, and to identify factors that influence the risk among survivors of childhood cancer...
  63. Belkacemi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff R. [Prognostic factors and management of rare cancers]. Cancer Radiother. 2006;10:323-9 pubmed
    ..The network gathers more than 70 institutions from 21 countries. So far, 32 projects have been carried out. In this report we will discuss the most significant data provided by our group in several investigated diseases...
  64. Einollahi B, Simforoosh N, Lessan Pezeshki M, Basiri A, Nafar M, Pour Reza Gholi F, et al. Genitourinary tumor following kidney transplantation: a multicenter study. Transplant Proc. 2009;41:2848-9 pubmed publisher
    ..There was a male predominance among TCC of the bladder and RCC (5:2 and 4:1, respectively). In conclusion, TCC of the bladder was the most common genitourinary tumor following kidney transplantation. It was predominant in male patients...
  65. Vaupel P, Hoeckel M, Mayer A. Oxygenation status of urogenital tumors. Adv Exp Med Biol. 2011;701:101-6 pubmed publisher
    ..In these benign tumors, the median pO(2) is 1 mmHg and signs of hypoxia-driven processes are missing...
  66. Climent M, Anido U, Méndez Vidal M, Puente J. Zoledronic acid in genitourinary cancer. Clin Transl Oncol. 2013;15:871-8 pubmed publisher
    ..Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer...
  67. Wilson S, Crawford E. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2005;22:485-513 pubmed
  68. Yedibela S, Gohl J, Graz V, Pfaffenberger M, Merkel S, Hohenberger W, et al. Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review. Ann Surg Oncol. 2005;12:778-85 pubmed
    ..The isolated occurrence of noncolorectal liver metastases is rare. The available data are inconsistent in terms of indication for surgery, treatment, and outcome, so a generally applicable therapeutic algorithm is currently lacking...
  69. Tsushima Y, Takano A, Taketomi Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol. 2007;14:643-50 pubmed
    ..To evaluate the potential usefulness of high b-value body diffusion-weighted images (DWIs) as a screening tool in the depiction of abdominal malignant tumors...
  70. Jiko M, Yano I, Sato E, Takahashi K, Motohashi H, Masuda S, et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol. 2007;12:284-90 pubmed
    ..We investigated the pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine in patients with urogenital cancer to clarify the significance of monitoring of the serum concentration of paclitaxel...
  71. Kim S, Kim H, Yang D. Imaging findings of ruptured abdominal and pelvic tumors. Acta Radiol. 2012;53:508-17 pubmed publisher
  72. Tan O, Carr B, Beshay V, Bukulmez O. The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review. Reprod Sci. 2013;20:16-25 pubmed publisher
    ..Comparative clinical data are required to explore their systemic effects on various extrapituitary tissues such as on cardiac function in the long term as well as their potential use in other human cancers that express GnRH receptors...
  73. Hegele A, Heinzer H, Ruttinger D, Siebels M. [DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?]. Aktuelle Urol. 2012;43:219-26 pubmed
  74. Sjakste N, Sjakste T, Vikmanis U. Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis. Exp Oncol. 2004;26:170-8 pubmed
    ..II. Tumors with phenotypic quantitative or qualitative changes of the NMP spectrum...
  75. Lu B, Lai M. [Landscaping the terrain of the Sino-Germany Symposium on new development on surgical and basic pathology]. Zhonghua Bing Li Xue Za Zhi. 2005;34:118-20 pubmed
  76. Ionescu S, Andrei B, Filip S, Nicoară D. [The role of minimally invasive surgery in the diagnosis and treatment of tumors in children]. Chirurgia (Bucur). 2008;103:503-8 pubmed
  77. Han Z, He H, Bi X, Qin W, Dai Q, Zou J, et al. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res. 2010;160:260-7 pubmed publisher
  78. Zenger M, Brix C, Borowski J, Stolzenburg J, Hinz A. The impact of optimism on anxiety, depression and quality of life in urogenital cancer patients. Psychooncology. 2010;19:879-86 pubmed publisher
    ..A further aim was to investigate the predictive value of optimism for anxiety, depression and HRQOL, quantified with and without controlling the corresponding base level...
  79. Shukla H, Tewari M. An evolution of clinical application of inferior pedicle based rectus abdominis myocutaneous flap for repair of perineal defects after radical surgery for cancer. J Surg Oncol. 2010;102:287-94 pubmed publisher
    ..Its use for reconstruction after Abdomino-perineal resection was first described in 1984. This review attempts to summarize the anatomic-technical aspects of inferiorly based RAMF and its applications...
  80. Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F. Biologic tools to personalize treatment in genitourinary cancers. Crit Rev Oncol Hematol. 2012;84 Suppl 1:e42-8 pubmed publisher
    ..Our goal is to clarify if biomarkers could be used at present to personalize treatment for GU cancers...
  81. Gurtowska N, Bajek A, Olkowska J, Drewa T. [Identification of circulating tumor cells as a promising method of genitourinary cancer diagnosis]. Postepy Hig Med Dosw (Online). 2012;66:983-90 pubmed
    ..The paper presents the characteristics of circulating tumor cell isolation methods and the results of studies concerning CTCs isolation in patients with prostate, bladder and kidney cancer. ..
  82. Pilarski R, Burt R, Kohlman W, Pho L, Shannon K, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607-16 pubmed publisher
    ..Our goal was to develop revised, evidence-based diagnostic criteria and to include features of the broader spectrum of PTEN-related clinical syndromes...
  83. Slovin S. Biomarkers for immunotherapy in genitourinary malignancies. Urol Oncol. 2016;34:205-13 pubmed publisher
    ..The issues faced by clinical investigators and the current state of immune monitoring are discussed. ..
  84. Harel M, Ferrer F, Shapiro L, Makari J. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma. Urol Oncol. 2016;34:103-15 pubmed publisher
    ..Ultimately, the most substantial progress may arise from further elucidation of genetic and molecular pathways involved in RMS tumor formation in an effort to identify novel, targeted therapeutic approaches. ..
  85. Okuda H, Toma H. [Treatment for the postrenal acute renal failure]. Nihon Rinsho. 2004;62 Suppl 5:426-34 pubmed
  86. Rebillard X, Tretarre B. [Epidemiology of urogenital cancers in France]. Rev Prat. 2007;57:595-602 pubmed
    ..Of all urological cancers, bladder cancers have the worst prognosis, since the relative five-year survival is 60% in men and especially 50% in women...
  87. Molnar V, Tamasi V, Bakos B, Wiener Z, Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin Cancer Biol. 2008;18:111-22 pubmed publisher
    ..Their relevance is described in detail in melanomas from the aspect of diagnosis, the potential application of miRNAs as biomarkers and as potential therapeutic tools...
  88. O Sullivan J, Sheridan J, Mulcahy H, Tenniswood M, Morrissey C. The effect of green tea on oxidative damage and tumour formation in Lobund-Wistar rats. Eur J Cancer Prev. 2008;17:489-501 pubmed publisher
  89. Yamamoto M, Barfod B, Urakawa Y. Gamma knife radiosurgery for brain metastases of non-lung cancer origin: focusing on multiple brain lesions. Prog Neurol Surg. 2009;22:154-69 pubmed publisher
    ..Although tumor number was demonstrated to have a significant impact on the duration of survival, approximately 85% of patients with brain metastases died of causes other than brain disease progression, regardless of tumor number...
  90. Platta C, Bayliss A, McHaffie D, Tome W, Straub M, Bradley K. A dosimetric analysis of tomotherapy based intensity modulated radiation therapy with and without bone marrow sparing in gynecologic malignancies. Technol Cancer Res Treat. 2013;12:19-29 pubmed
    ..Further investigation is warranted to determine if rates of hematologic toxicity improve with utilization of Tomotherapy based BMS-IMRT...
  91. Yust Katz S, Mathis S, Groves M. Leptomeningeal metastases from genitourinary cancer: the University of Texas MD Anderson Cancer Center experience. Med Oncol. 2013;30:429 pubmed publisher
    ..Although rare-LM should be considered as a complication of GU cancer. Awareness of early neurological signs and symptoms may help the clinician to make an early diagnosis and possibly intervene to prevent neurological deficits...
  92. Hoyt B, Cohen P. Cutaneous scrotal metastasis: origins and clinical characteristics of visceral malignancies that metastasize to the scrotum. Int J Dermatol. 2013;52:398-403; quiz 403-5 pubmed publisher
    ..Treatment is often unsuccessful, and the mean patient survival following scrotal metastasis is <4 months...